Reuters logo
U.S. court invalidates patent on Bristol hepatitis B drug
February 12, 2013 / 2:55 PM / 5 years ago

U.S. court invalidates patent on Bristol hepatitis B drug

Feb 12 (Reuters) - A U.S. federal court has invalidated the patent on Bristol-Myers Squibb Co’s Baraclude treatment for hepatitis B after a challenge from generic drugmaker Teva Pharmaceutical Industries Ltd, Bristol-Myers said on Tuesday.

“We are disappointed with the court’s decision and believe it is incorrect,” Bristol-Myers spokeswoman Laura Hortas said. She said her company is considering whether to appeal the ruling by the U.S. District Court in Delaware.

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below